Company news

Aptose Biosciences Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical

June 30, 2026

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

June 15, 2026

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

May 29, 2026

Aptose Reports First Quarter 2026 Results

May 13, 2026

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

April 30, 2026

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

March 31, 2026

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

March 23, 2026

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical

March 19, 2026

Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders

February 24, 2026

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

December 19, 2025

Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

December 6, 2025

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

November 19, 2025

Aptose Reports Third Quarter 2025 Results

November 13, 2025

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

August 22, 2025

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

August 1, 2025

Aptose Biosciences announces results of annual and special meeting of shareholders

June 10, 2015

Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia

June 2, 2015

Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015

May 5, 2015

Aptose Biosciences To Host First Quarter Ended March 31, 2015 Financial Results Conference Call and Webcast

April 30, 2015

Aptose Biosciences Announces Appointment of Dr. Michael Andreeff to Scientific Advisory Board

March 23, 2015

Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference

March 23, 2015

Aptose Biosciences to Present at the 27th Annual ROTH Conference

March 5, 2015

Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014

March 3, 2015

Aptose Biosciences To Host Quarter and Seven Month Transition Period Ended December 31, 2014 Conference Call and Webcast

February 26, 2015

Aptose Biosciences to Present at the Cowen & Company 35th Annual Healthcare Conference

February 25, 2015

Aptose Biosciences to Present at the RBC Capital Markets 2015 Global Healthcare Conference

February 19, 2015

Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee

January 20, 2015

Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies

January 13, 2015

Aptose Biosciences to Present at Biotech Showcase(TM) 2015

January 12, 2015

Aptose Biosciences Announces Appointment of Dr. Erich Platzer to Board of Directors

December 15, 2014

Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting

December 9, 2014

Aptose Biosciences to Present at Oppenheimer & Co. 25th Annual Healthcare Conference

December 5, 2014

Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting

December 3, 2014

Aptose Biosciences to Present at The Stifel 2014 Healthcare Conference

November 17, 2014

Aptose Biosciences reports results for the four months ended September 30, 2014

November 4, 2014

Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014

October 30, 2014

Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO

October 21, 2014

Aptose Biosciences to Present at the 2014 BIO Investor Forum

October 3, 2014

Aptose Biosciences Announces Reverse Stock Split

October 1, 2014

Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative with Oregon Health & Science University

September 29, 2014

Aptose Biosciences to Present at Upcoming Investor Conferences

September 25, 2014

Aptose Biosciences Recruits Stephen B. Howell, M.D. to Act in the Capacity of Chief Medical Officer

September 8, 2014

Lorus Therapeutics Implements Name Change to Aptose Biosciences

September 2, 2014

Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders

August 19, 2014

Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing

July 15, 2014

Investment Industry Regulatory Organization of Canada - Trade Resumption - Lorus Therapeutics - LOR

June 21, 2011

Investment Industry Regulatory Organization of Canada - Trading Halt - Lorus Therapeutics - LOR

June 21, 2011

Investment Industry Regulatory Organization of Canada - Trade Resumption - Lorus Therapeutics Inc. - LOR

December 1, 2010

Investment Industry Regulatory Organization of Canada - Trading Halt - Lorus Therapeutics Inc. - LOR

December 1, 2010

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.